Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301873 · ClinicalTrials.gov registry record · Phase 2
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
A Phase 2 study of Osteoporosis and Brain Tumors, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00301873 is a Phase 2 study of Osteoporosis and Brain Tumors that has completed, run by Duke University. The registered enrollment target is 60 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00301873, a Phase 2 study of Osteoporosis and Brain Tumors, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
Conditions Studied
Interventions
- DRUG IV Zometa
Study Locations (1)
North Carolina
- Duke Comprehensive Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00301873
The ClinicalTrials.gov registry entry for NCT00301873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which IV Zometa is the first listed.
NCT00301873 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00301873 about?
NCT00301873 is a clinical study titled "Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma". RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
What is the current status of trial NCT00301873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-05. Estimated completion is 2012-09.
What conditions does trial NCT00301873 study?
This clinical trial studies the following conditions: Osteoporosis, Brain Tumors, Central Nervous System(CNS)Malignancies.
What interventions are being tested in trial NCT00301873?
The interventions under investigation include: IV Zometa (DRUG).
Who is sponsoring clinical trial NCT00301873?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00301873 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
RECRUITING · Phase 2
-
Calcium and Bone Mass in Young Females
COMPLETED · Phase 2
-
Comparison Study of PTHrP and PTH to Treat Osteoporosis
COMPLETED · Phase 2
-
Hormone Replacement Therapy to Treat Turner Syndrome
COMPLETED · Phase 2
-
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
COMPLETED · Phase 2
-
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.